[Source: Journal of Antimicrobial Chemotherapy, full page: (LINK). Summary, edited.]
Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae
Aurélie Jayol, Patrice Nordmann, Laurent Poirel, Véronique Dubois
Journal of Antimicrobial Chemotherapy, dkx393, https://doi.org/10.1093/jac/dkx393
Published: 18 November 2017
The spread of carbapenemase-producing Klebsiella pneumoniae is a major public health concern since such isolates are basically resistant to most available antibiotics, including β-lactams, fluoroquinolones and aminoglycosides.1 Infections due to carbapenemase-producing K. pneumoniae are therefore commonly treated with a regimen containing colistin.1 However, acquired resistance to colistin now occurs frequently and has few therapeutic options.2 Outbreaks with colistin-resistant and carbapenemase-producing K. pneumoniae isolates have been reported worldwide2 and mortality rates are high owing to limited treatment options.3
Issue Section: Research letter
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: email@example.com.
Keywords: Antibiotics; Drugs Resistance; Klebsiella Pneumoniae; Colistin; Carbapenem; Aztreonam; Ceftazidime; Avibactam.